1. Home
  2. TSLX vs IBRX Comparison

TSLX vs IBRX Comparison

Compare TSLX & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TSLX
  • IBRX
  • Stock Information
  • Founded
  • TSLX 2010
  • IBRX 2014
  • Country
  • TSLX United States
  • IBRX United States
  • Employees
  • TSLX N/A
  • IBRX N/A
  • Industry
  • TSLX Investment Managers
  • IBRX Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • TSLX Finance
  • IBRX Health Care
  • Exchange
  • TSLX Nasdaq
  • IBRX Nasdaq
  • Market Cap
  • TSLX 2.1B
  • IBRX 2.3B
  • IPO Year
  • TSLX 2014
  • IBRX N/A
  • Fundamental
  • Price
  • TSLX $24.41
  • IBRX $2.93
  • Analyst Decision
  • TSLX Strong Buy
  • IBRX Strong Buy
  • Analyst Count
  • TSLX 8
  • IBRX 5
  • Target Price
  • TSLX $22.69
  • IBRX $11.40
  • AVG Volume (30 Days)
  • TSLX 587.3K
  • IBRX 6.8M
  • Earning Date
  • TSLX 07-30-2025
  • IBRX 08-11-2025
  • Dividend Yield
  • TSLX 8.53%
  • IBRX N/A
  • EPS Growth
  • TSLX N/A
  • IBRX N/A
  • EPS
  • TSLX 1.89
  • IBRX N/A
  • Revenue
  • TSLX $481,092,000.00
  • IBRX $31,222,000.00
  • Revenue This Year
  • TSLX N/A
  • IBRX $567.98
  • Revenue Next Year
  • TSLX N/A
  • IBRX $160.56
  • P/E Ratio
  • TSLX $12.92
  • IBRX N/A
  • Revenue Growth
  • TSLX 4.73
  • IBRX 10238.41
  • 52 Week Low
  • TSLX $18.58
  • IBRX $1.83
  • 52 Week High
  • TSLX $25.17
  • IBRX $7.48
  • Technical
  • Relative Strength Index (RSI)
  • TSLX 56.28
  • IBRX 58.60
  • Support Level
  • TSLX $24.13
  • IBRX $2.64
  • Resistance Level
  • TSLX $24.59
  • IBRX $2.94
  • Average True Range (ATR)
  • TSLX 0.30
  • IBRX 0.17
  • MACD
  • TSLX -0.06
  • IBRX 0.03
  • Stochastic Oscillator
  • TSLX 33.38
  • IBRX 75.53

About TSLX Sixth Street Specialty Lending Inc.

Sixth Street Specialty Lending Inc is a specialty finance company focused on providing flexible, fully committed financing solutions to middle market companies located in the United States of America. It partners with companies across a variety of industries and excel at providing creative solutions to companies with complex business models that may have limited access to capital. The company seeks to generate current income in U.S.-domiciled middle-market companies through direct originations of senior secured loans and, to a lesser extent, originations of mezzanine and unsecured loans and investments in corporate bonds and equity securities.

About IBRX ImmunityBio Inc.

ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.

Share on Social Networks: